HB0034 in Patients With Generalized Pustular Psoriasis (GPP)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 6, 2022

Primary Completion Date

November 15, 2023

Study Completion Date

January 10, 2024

Conditions

Generalized Pustular Psoriasis

Interventions

DRUG

HB0034

HB0034, a single dose

Trial Locations (1)

Dermatology Hospital of Shandong First Medical University, Shandong

All Listed Sponsors

lead

Shanghai Huaota Biopharmaceutical Co., Ltd.

INDUSTRY